DIORIO CHRIS PH.D.

SEC source: 0001677721-25-000005 · form4-09192025_090952.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,088

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001677721-25-000005 · form4-09192025_090952.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 344,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 10

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,013

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $191.61 to $191.77, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,025

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.0001 to $190.545, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 297,365

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.82 to $189.615, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 298,215

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.335 to $188.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 299,288

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $186.045 to $186.8101, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 301,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $183.30 to $183.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 301,905

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $182.30 to $183.245, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 303,165

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $181.24 to $182.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 305,074

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $180.235 to $180.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000004 · form4-09162025_080936.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 305,541

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $179.00 to $179.665, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001677721-25-000003 · form4-09162025_080900.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 306,109

F1 · kind: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's 0% Convertible Senior Notes offering in September 2025, the Reporting Person is permitted to gift up to 30,000 common shares beneficially owned during the lock-up period.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 12

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 11

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,276

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $197.78 to $198.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 10

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 336,579

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $196.76 to $197.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 337,369

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $195.75 to $196.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 337,618

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $194.71 to $195.6975, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 338,738

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $193.635 to $194.62, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 340,070

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $192.455 to $193.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 340,580

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $191.25 to $191.37, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 340,779

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.19 to $190.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 341,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 341,209

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $192.17 to $193.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-024010 · form4-09092025_110943.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 344,216

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $191.17 to $192.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 346,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.0000 to $190.4050, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 348,666

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.9201 to $189.8300, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 350,104

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.8650 to $188.4050, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 351,029

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 351,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $181.185 to $181.54, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023612 · form4-09042025_120914.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 351,592

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.82, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 9

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,309

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.10 to $189.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 359,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.00.00 to $188.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,109

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.75 to $190.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 5

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,179

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.70 to $190.675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 361,504

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.585 to $189.335, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 362,464

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.5801 to $188.57 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 364,213

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $186.43 to $187.305, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-023326 · form4-08292025_110828.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 364,997

F1 · kind: The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $185.34.00 to $186.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-25-022639 · form4-08212025_090833.xml · derivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,015

Underlying: Common Stock · 15,015 shares

Expires not disclosed

F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Impinj common stock.

F2 · derivative.exercise_date: One-fourth of the shares subject to the grant shall vest on August 20, 2026, and 1/16th of the shares subject to the grant shall vest each quarter thereafter, subject to the reporting person's continued service to the Issuer through such date.

F2 · derivative.expiration_date: One-fourth of the shares subject to the grant shall vest on August 20, 2026, and 1/16th of the shares subject to the grant shall vest each quarter thereafter, subject to the reporting person's continued service to the Issuer through such date.

SEC source: 0001415889-25-018134 · form4-06242025_110601.xml · derivative · entry 8

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,990

Underlying: Common Stock · 1,817 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Impinj common stock.

F5 · derivative.exercise_date: On March 23, 2024, the reporting person was granted 29,075 RSUs. One-sixteenth of these vested on June 23, 2025.

F5 · derivative.expiration_date: On March 23, 2024, the reporting person was granted 29,075 RSUs. One-sixteenth of these vested on June 23, 2025.

SEC source: 0001415889-25-018134 · form4-06242025_110601.xml · derivative · entry 7

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,567

Underlying: Common Stock · 1,223 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Impinj common stock.

F4 · derivative.exercise_date: On March 23, 2023, the reporting person was granted 19,580 RSUs. One-sixteenth of these vested on June 23, 2025.

F4 · derivative.expiration_date: On March 23, 2023, the reporting person was granted 19,580 RSUs. One-sixteenth of these vested on June 23, 2025.

SEC source: 0001415889-25-018134 · form4-06242025_110601.xml · derivative · entry 6

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,782

Underlying: Common Stock · 2,593 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Impinj common stock.

F3 · derivative.exercise_date: On March 23, 2022, the reporting person was granted 41,500 RSUs. One-sixteenth of these vested on June 23, 2025.

F3 · derivative.expiration_date: On March 23, 2022, the reporting person was granted 41,500 RSUs. One-sixteenth of these vested on June 23, 2025.

SEC source: 0001415889-25-018134 · form4-06242025_110601.xml · nonDerivative · entry 4

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,109

F1 · kind: In an exempt disposition to the Issuer under Rule 16b-3(e), the Reporting Person remitted shares to the Issuer in connection with the satisfaction of tax withholding obligations arising out of the vesting of restricted stock units, or RSUs.

SEC source: 0001415889-25-018134 · form4-06242025_110601.xml · nonDerivative · entry 3

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 368,327

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-018134 · form4-06242025_110601.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-018134 · form4-06242025_110601.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,287

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-011967 · form4-05052025_080542.xml · nonDerivative · entry 1

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Indirect · by DFT L.L.C.

Disclosed balance after: 199,362

F1 · kind: Distribution of shares of Common Stock held in a trust managed by an independent trustee for the benefit of the reporting person's descendants by DFT L.L.C. for no consideration. Following the transaction, the reporting person is no longer the beneficial owner of the shares of Common Stock.

SEC source: 0001415889-25-010645 · form4-04142025_110405.xml · nonDerivative · entry 2

DIORIO CHRIS PH.D. · CIK 0001677721 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 362,694

F1 · kind: In an exempt disposition to the Issuer under Rule 16b-3(e), the Reporting Person remitted shares to the Issuer in connection with the satisfaction of tax withholding obligations arising out of the vesting of restricted stock units, or RSUs.